Ocon Therapeutics is a women's health company developing, manufacturing, and commercializing 3D drug delivery systems based on its patented IUB (Intra-Uterine Ball) platform. Its validated 3D stent drug delivery frame, the IUB Ballerine, has demonstrated safety and usability in over 150,000 women. The company is advancing IUB SEAD and IUB PRIMA assets designed to address abnormal and heavy uterine bleeding. These assets aim to provide long-term hormonal and short-term non-hormonal treatment options. The company recently raised $10M in funding led by RH Capital and intends to use the proceeds to further enhance its ability to provide solutions for prevalent uterine pathologies. Ocon is led by CEO Keren Leshem and is based in Modiin, Israel. OCON Healthcare develops Ballerine®, a 3D spherical copper intrauterine contraceptive (IUB) designed to reduce endometrial irritation and lower rates of malposition and perforation versus current T‑shaped IUDs. The company also develops SEAD™, a point‑of‑care therapy for abnormal uterine bleeding and is advancing SEAD through Phase II clinical trials. Rhia Ventures' investment is intended to support OCON's US launch of Ballerine and to expand Phase II work on SEAD. OCON is Israeli‑based and positions its products as hormone‑free, non‑invasive alternatives to existing contraceptives. The financing comes from RH Capital Fund II, an impact venture fund focused on contraceptive innovation, maternal health, and unmet needs in women's reproductive health. Company leadership cites the investment, partnership, and network from Rhia Ventures as enabling continued product innovation and market entry efforts.

Total raised

$10M

Funding rounds

2

Latest round

Equity

Latest activity

Jun 2024